Clinical trial status of Ruxolitinib Tablets/Jiekewei

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib), as a JAK1/2 inhibitor, has undergone extensive clinical research and trials in multiple fields since its launch. These clinical trials mainly focus on the efficacy, safety and long-term effects of ruxolitinib in diseases such as myelofibrosis (MF) and polycythemia vera (PV).

In the treatment of myelofibrosis, clinical research on ruxolitinib has achieved remarkable results. Multiple randomized controlled trials have shown that ruxolitinib can significantly improve the symptoms of patients with myelofibrosis, reduce splenomegaly, improve anemia symptoms, and significantly extend progression-free survival (PFS). One of the most well-known clinical trials is the JAKARTA trial, which evaluated ruxolitinib in the treatment of moderate to advanced myelofibrosis. Trial results show that ruxolitinib can significantly improve patients' quality of life and effectively control disease progression in most patients.

For polycythemia vera, clinical trials of ruxolitinib have also shown good efficacy. Trial results show that ruxolitinib can effectively control the excessive proliferation of red blood cells, reduce patients' symptoms and reduce the risk of blood clots. Especially in some refractory patients, ruxolitinib provides an effective treatment option and changes the treatment strategy.

In other diseasesRuxolitinib has also shown good results in clinical studies, especially in patients who are ineffective or intolerant to traditional treatments such as hydroxyurea. By inhibiting the JAK-STAT pathway, ruxolitinib can rapidly reduce platelet counts and reduce the risk of thrombosis and bleeding.

In addition to the research on the above main indications, clinical trials of ruxolitinib also cover other related blood diseases, such as thrombocythemia (ET) etc. In these studies, the efficacy of ruxolitinib as a precise targeted therapy has been further verified.

Reference materials:https://www.jakavi.com/